MarketCapExport financials
Akebia Therapeutics (AKBA)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Akebia Therapeutics Balance Sheet 2025-2011 | AKBA
Brief balance sheet overview of Akebia Therapeutics
This overview follows the five latest available annual observations between 2021 and 2025.
Assets fell from $529.3 million to $376.6 million. This may reflect either deliberate optimization or a reduction in business scale.
Assets and liabilities changed at similar rates, -28.9% and -24.5%. The funding mix did not shift sharply.
Equity covers only 8.7% of assets versus 14% initially. The loss-absorbing cushion is limited.
The period ended with net cash: net debt stood at -$133 million. This supports financial flexibility.
Cash equals 49.1% of the balance sheet, compared with 28.3% five periods ago. This is the readily available cushion.
The balance sheet carries negative retained earnings of -$1.7 billion. The figure may result from accumulated losses or an active capital return policy.
What the balance sheet shows
Akebia Therapeutics has limited balance sheet resilience and depends heavily on cash generation and refinancing capacity.
Annual Balance Sheet Akebia Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-133 M | -7.78 M | -21.3 M | -51.6 M | -111 M | -127 M | -39.1 M | -89.6 M | -70.2 M | -187 M | -49.8 M | -32.8 M | -21.2 M | -1.64 M | - |
Long Term Debt |
48.2 M | 38.7 M | 17.2 M | 34.1 M | 33.7 M | 96.4 M | 75.8 M | - | - | - | - | - | - | - | - |
Long Term Debt Current |
3.55 M | 5.4 M | 4.49 M | 4.74 M | 4.8 M | 5.29 M | 4.99 M | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | 168 M | 94.9 M | 101 M | 118 M | 74 K | 32 K | 8 K | - | - |
Total Current Liabilities |
163 M | 80.9 M | 99.9 M | 130 M | 261 M | 187 M | 208 M | 266 M | 144 M | 114 M | 11.9 M | 6.88 M | - | - | - |
Total Liabilities |
344 M | 270 M | 272 M | 351 M | 455 M | 397 M | 376 M | 361 M | 245 M | 232 M | 11.9 M | 6.92 M | 3.91 M | 4.92 M | - |
Deferred Revenue |
2.68 M | - | - | 3.74 M | 20.9 M | 15.2 M | 39.8 M | 57 M | 84.9 M | 82 M | - | - | - | - | - |
Retained Earnings |
-1.68 B | -1.68 B | -1.61 B | -1.56 B | -1.46 B | -1.18 B | -794 M | -514 M | -374 M | -297 M | -161 M | -101 M | -63.7 M | -59.6 M | - |
Total Assets |
377 M | 221 M | 242 M | 356 M | 529 M | 644 M | 771 M | 997 M | 364 M | 300 M | 143 M | 111 M | 34.7 M | 2.24 M | - |
Cash and Cash Equivalents |
185 M | 51.9 M | 42.9 M | 90.5 M | 150 M | 229 M | 147 M | 105 M | 70.2 M | 187 M | 49.8 M | 32.8 M | 21.2 M | 1.64 M | - |
Book Value |
32.6 M | -49.2 M | -30.6 M | 5.23 M | 74 M | 248 M | 395 M | 636 M | 119 M | 68.1 M | 131 M | 104 M | 30.8 M | -2.68 M | - |
Total Shareholders Equity |
32.6 M | -49.2 M | -30.6 M | 5.23 M | 74 M | 244 M | 395 M | 636 M | 123 M | 68.1 M | 131 M | 104 M | -127 M | -59.6 M | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Balance Sheet Akebia Therapeutics
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
24.8 M | 36.4 M | 47.6 M | 47.1 M | 46.5 M | 38.7 M | 38.4 M | 38 M | - | 17.2 M | 34.6 M | 18.5 M | 26.3 M | 34.1 M | 65.9 M | - | 32.6 M | 33.7 M | 97.2 M | 96.9 M | 96.6 M | 96.4 M | 96.4 M | 96.4 M | 96.4 M | 75.8 M | 75.8 M | 75.8 M | 75.8 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
325 M | 335 M | 323 M | 316 M | 286 M | 270 M | 258 M | 254 M | - | 272 M | 274 M | 281 M | 291 M | 351 M | 422 M | 471 M | 509 M | 449 M | 465 M | 437 M | 415 M | 397 M | 397 M | 397 M | 397 M | 376 M | 376 M | 376 M | 376 M | 361 M | 361 M | 361 M | 361 M | 242 M | 242 M | 242 M | 242 M | 232 M | 232 M | 232 M | 232 M | 11.9 M | 11.9 M | 11.9 M | 11.9 M | 6.92 M | 6.92 M | 6.92 M | 6.92 M | 3.91 M | 3.91 M | 3.91 M | 3.91 M | - | - | - | - | - | - | - | - |
Deferred Revenue |
6.17 M | 4.5 M | 3.88 M | 5.53 M | 1.24 M | - | - | 43.3 M | - | - | - | - | - | 3.74 M | 1.26 M | - | 10.4 M | 20.9 M | 15.7 M | 11.9 M | 18.3 M | 15.2 M | 15.2 M | 15.2 M | 15.2 M | 39.8 M | 39.8 M | 39.8 M | 39.8 M | 57 M | 57 M | 78.6 M | 78.6 M | 81.7 M | 121 M | 142 M | 81.7 M | 82 M | 82 M | 82 M | 82 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-1.7 B | -1.69 B | -1.67 B | -1.67 B | -1.67 B | -1.68 B | -1.66 B | -1.64 B | - | -1.61 B | -1.61 B | -1.6 B | -1.58 B | -1.56 B | -1.55 B | -1.5 B | -1.52 B | -1.46 B | -1.39 B | -1.33 B | -1.25 B | -1.18 B | -1.18 B | -1.18 B | -1.18 B | -794 M | -794 M | -794 M | -794 M | -514 M | -514 M | -514 M | -514 M | -371 M | -371 M | -371 M | -371 M | -297 M | -297 M | -297 M | -297 M | -161 M | -161 M | -161 M | -161 M | -101 M | -101 M | -101 M | -101 M | -127 M | -127 M | -127 M | - | - | - | - | - | - | - | - | - |
Total Assets |
350 M | 363 M | 364 M | 346 M | 310 M | 221 M | 207 M | 220 M | - | 242 M | 235 M | 254 M | 277 M | 356 M | 436 M | 530 M | 535 M | 526 M | 602 M | 612 M | 629 M | 644 M | 644 M | 644 M | 644 M | 771 M | 771 M | 771 M | 771 M | 997 M | 997 M | 997 M | 997 M | 364 M | 364 M | 364 M | 364 M | 300 M | 300 M | 300 M | 300 M | 143 M | 143 M | 143 M | 143 M | 111 M | 111 M | 111 M | 111 M | 34.7 M | 34.7 M | 34.7 M | 34.7 M | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
156 M | 163 M | 166 M | 137 M | 113 M | 51.9 M | 35.7 M | 41.2 M | 43.6 M | 42.9 M | 48.2 M | 55.3 M | 57 M | 90.5 M | 148 M | 147 M | 178 M | 150 M | 209 M | 247 M | 253 M | 229 M | 229 M | 229 M | 229 M | 147 M | 147 M | 147 M | 147 M | 105 M | 105 M | 105 M | 105 M | 70.2 M | 70.2 M | 70.2 M | 70.2 M | 187 M | 187 M | 187 M | 187 M | 49.8 M | 49.8 M | 49.8 M | 49.8 M | 32.8 M | 32.8 M | 32.8 M | 32.8 M | 21.2 M | 21.2 M | 21.2 M | 21.2 M | 1.64 M | - | - | - | 5.01 M | - | - | - |
Book Value |
25 M | 27.4 M | 41.6 M | 29.2 M | 24.6 M | -49.2 M | -50.4 M | -33.8 M | - | -30.6 M | -39.4 M | -26.8 M | -14.4 M | 5.23 M | 13.9 M | 58.9 M | 26.1 M | 76.5 M | 137 M | 175 M | 214 M | 248 M | 248 M | 248 M | 248 M | 395 M | 395 M | 395 M | 395 M | 636 M | 636 M | 636 M | 636 M | 123 M | 123 M | 123 M | 123 M | 68.1 M | 68.1 M | 68.1 M | 68.1 M | 131 M | 131 M | 131 M | 131 M | 104 M | 104 M | 104 M | 104 M | 30.8 M | 30.8 M | 30.8 M | 30.8 M | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
25 M | 27.4 M | 41.6 M | 29.2 M | 24.6 M | -49.2 M | -50.4 M | -33.8 M | -27.3 M | -30.6 M | -39.4 M | -26.8 M | -14.4 M | 5.23 M | 8.26 M | 58.9 M | 26.1 M | 76.5 M | 137 M | 175 M | 214 M | 248 M | 248 M | 248 M | 248 M | 395 M | 395 M | 395 M | 395 M | 636 M | 636 M | 636 M | 636 M | 123 M | 123 M | 123 M | 123 M | 68.1 M | 68.1 M | 68.1 M | 68.1 M | 131 M | 131 M | 131 M | 131 M | 104 M | 104 M | 104 M | 104 M | -127 M | -127 M | -127 M | -127 M | -59.6 M | - | - | - | -48.2 M | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Balance Sheet is a fundamental financial report of Akebia Therapeutics, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
Russia
USA
Canada
Niderland
France
Israel
Australia
Irlanda
Danmark
